Susan Randall Armel

Susan Randall Armel

Auto-generated profile, based on publicly available information

Susan Randall Armel


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2018 in Cancers
Verified
Journal Article
Open access
PDF file
JMJeanna McCuaig
Jeanna McCuaig
SASusan Randall Armel
Susan Randall Armel
MCMelanie Care
Melanie Care
AVAlexandra Volenik
Alexandra Volenik
RKRaymond Kim
Raymond Kim
KMKelly A Metcalfe
Kelly A Metcalfe
The combination of increased referral for genetic testing and the current shortage of genetic counselors has necessitated the development and implementation of alternative models of genetic counseling and testing for hereditary cancer assessment. The purpose of this scoping review is to provide an overview of the patient outcomes that are associated with alternative models of genetic testing and genetic counseling for hereditary cancer, including germline-only and tumor testing models. Seven databases were searched, selecting studies that were: (1) full-text articles published ≥2007 or conference abstracts published ≥2015, and (2) assessing patient outcomes of an alternative model of genetic counseling or testing. A total of 79 publications were included for review and synthesis. Data-charting was completed using a data-charting form that was developed by the study team for this review. Seven alternative models were identified, including four models that involved a genetic counselor: telephone, telegenic, group, and embedded genetic counseling models; and three models that did not: mainstreaming, direct, and tumor-first genetic testing models. Overall, these models may be an acceptable alternative to traditional models on knowledge, patient satisfaction, psychosocial measures, and the uptake of genetic testing; however, particular populations may be better served by traditional in-person genetic counseling. As precision medicine initiatives continue to advance, institutions should consider the implementation of new models of genetic service delivery, utilizing a model that will best serve the needs of their unique patient populations.

8 April 2021 in Current Oncology
Verified
Journal Article
Open access
PDF file
JMJeanna McCuaig
Jeanna McCuaig
ETEmily Thain
Emily Thain
JMJanet Malcolmson
Janet Malcolmson
SKSareh Keshavarzi
Sareh Keshavarzi
SASusan Randall Armel
Susan Randall Armel
RKRaymond Kim
Raymond Kim
This study compares knowledge, experience and understanding of genetic testing, and psychological outcomes among breast and ovarian cancer patients undergoing multi-gene panel testing via genetic counselor-mediated (GMT) or oncologist-mediated (OMT) testing models. A pragmatic, prospective survey of breast and ovarian cancer patients pursuing genetic testing between January 2017 and August 2019 was conducted at the Princess Margaret Cancer Centre in Toronto, Canada. A total of 120 (80 GMT; 40 OMT) individuals completed a survey administered one week following consent to genetic testing. Compared to OMT, the GMT cohort had higher median knowledge (8 vs. 9; p = 0.025) and experience/understanding scores (8.5 vs. 10; p < 0.001) at the time of genetic testing. Significant differences were noted in the potential psychological concerns experienced, with individuals in the GMT cohort more likely to screen positive in the hereditary predisposition domain of the Psychosocial Aspects of Hereditary Cancer tool (55% vs. 27.5%; p = 0.005), and individuals in the OMT cohort more likely to screen positive in the general emotions domain (65.0% vs. 38.8%; p = 0.007). The results of this study suggest that OMT can be implemented to streamline genetic testing; however, post-test genetic counseling should remain available to all individuals undergoing genetic testing, to ensure any psychologic concerns are addressed and that individuals have a clear understanding of relevant implications and limitations of their test results.

1 June 2015 in Gynecologic Oncology
Verified
Journal Article
Closed access
EFE. Fox
E. Fox
JMJ. McCuaig
J. McCuaig
RDR. Demsky
R. Demsky
CSC. Shuman
C. Shuman
DCD. Chitayat
D. Chitayat
SAS. Randall Armel
S. Randall Armel

1 August 2020 in Gynecologic Oncology
Verified
Journal Article
Closed access
SASusan Randall Armel
Susan Randall Armel
AVAlexandra Volenik
Alexandra Volenik
RDRochelle Demsky
Rochelle Demsky
JMJanet Malcolmson
Janet Malcolmson
MMManjula Maganti
Manjula Maganti
JMJeanna McCuaig
Jeanna McCuaig

17 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
EGEmma Guyonnet
Emma Guyonnet
SKShana J. Kim
Shana J. Kim
KPKatherine Pullella
Katherine Pullella
CZCindy X. W. Zhang
Cindy X. W. Zhang
JMJeanna McCuaig
Jeanna McCuaig
Joanne KotsopoulosJoanne Kotsopoulos
Joanne Kotsopoulos
The role of vitamin D and calcium use in the development of breast cancer among women in the general population is not clear. Furthermore, whether vitamin D and calcium supplement use are associated with breast cancer in high-risk populations has not been evaluated. Thus, we evaluated the association between vitamin D and/or calcium supplement use and breast cancer among women with a pathogenic variant (mutation) in BRCA1 or BRCA2. BRCA mutation carriers enrolled in a longitudinal study were invited to complete a supplemental questionnaire on lifetime supplement use. Cases included women with a prevalent diagnosis of invasive breast cancer, and controls had no history of breast cancer. Vitamin D and calcium use were categorized as never/ever use, and as tertiles of supplement intake (total average daily supplement use). Unconditional logistic regression was used to estimate the odds ratio (OR) and 95% confidence intervals (CIs) of breast cancer. This study included 134 breast cancer cases and 276 controls. Women who used vitamin D-containing supplements had 46% lower odds of having breast cancer compared to those who never used supplements (OR 0.54; 95% CI 0.31, 0.91; p = 0.02). Increasing vitamin D and calcium supplement intake was inversely associated with the odds of having breast cancer (p-trend = 0.04). Findings were suggestively stronger among BRCA1 mutation carriers; however, analyses were limited by small strata. These findings suggest a potential inverse association between vitamin D and calcium supplementation and BRCA breast cancer. Additional studies are warranted to confirm these findings and accurately inform clinical care guidelines.

1 July 2021 in Gynecologic Oncology
Verified
Journal Article
Closed access
Alicia ToneAlicia Tone
Alicia Tone
JMJeanna McCuaig
Jeanna McCuaig
NRNicole Ricker
Nicole Ricker
TBTalin Boghosian
Talin Boghosian
TRTina Romagnuolo
Tina Romagnuolo
MBMarcus Q Bernardini
Marcus Q Bernardini